Asieris Pharmaceuticals, a global innovative biopharma company, announced that Hexvix, a drug for diagnosis of for bladder cancer has obtained the clinical trial application (CTA) approval from the National Medical Products Administration (NMPA) of China.
The study is a prospective, self-controlled, multicenter phase ? trial aimed to investigate the additional detection rate and safety of Hexvix and blue light cystoscopy (BLC) versus white light cystoscopy in patients with non-muscle invasive bladder cancer (NMIBC) (CIS, Ta, T1). The study will be led by Peking Union Medical College Hospital, Chinese Academy of Medical Sciences. Professor Li Hanzhong, head of the Department of Surgery, Peking Union Medical College Hospital, will serve as the Principal Investigator to lead a team of top experts in the field of bladder cancer in China to carry out this study. The company plans to file a new drug application to the NMPA in the future pending clinical trial progress and meaningful data.
According to the 2020 global cancer data released by the World Health Organization
